Rationale: Intracranial hypertension affects around 80% of patients in the acute phase and causes headache, diplopia, and, in severe cases, visual loss.4,91 Acetazolamide, topiramate, and glucagon-like peptide-1 (GLP-1) receptor agonists can reduce production of cerebral spinal fluid and may reduce intracranial pressure and prevent vision loss.92, –94 The efficacy and safety of these drugs in patients with CVT for the treatment of intracranial hypertension, both in the acute and chronic phase, have not been properly investigated. This evidence concerns the gene GLP1R and intracranial hypertension.